Risk Factors Associated with Post-kidney Transplant Malignancies: an Article from the Cancer-Kidney International Network

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2018 Jun 27

PMID 29942495

Citations 51

Authors

Ben Sprangers

Vinay Nair

Vincent Launay-Vacher

Leonardo V Riella

Kenar D Jhaveri

Affiliations

Soon will be listed here.

Abstract

In kidney transplant recipients, cancer is one of the leading causes of death with a functioning graft beyond the first year of kidney transplantation, and malignancies account for 8-10% of all deaths in the USA (2.6 deaths/1000 patient-years) and exceed 30% of deaths in Australia (5/1000 patient-years) in kidney transplant recipients. Patient-, transplant- and medication-related factors contribute to the increased cancer risk following kidney transplantation. While it is well established that the overall immunosuppressive dose is associated with an increased risk for cancer following transplantation, the contributive effect of different immunosuppressive agents is not well established. In this review we will discuss the different risk factors for malignancies after kidney transplantation.

Citing Articles

Predictors of self-care in kidney transplant patients according to preoperative dialysis: A comparative study.

Im H, Jang H Heliyon. 2025; 10(24):e40237.

PMID: 39802610 PMC: 11724763. DOI: 10.1016/j.heliyon.2024.e40237.

Acute Allograft Rejection in Kidney Transplant Recipients Treated With Immune Checkpoint Inhibitors: An Educational Case Report.

Morrison S, Vinson A Can J Kidney Health Dis. 2024; 11:20543581241289191.

PMID: 39444717 PMC: 11497508. DOI: 10.1177/20543581241289191.

Glycolysis Changes in Alloreactive Memory B Cells in Highly Sensitized Kidney Transplant Recipients Undergoing Desensitization Therapy.

Noble J, Cabezas L, Truffot A, Dumolard L, Jouve T, Malvezzi P Transpl Int. 2024; 37:13029.

PMID: 39081904 PMC: 11287219. DOI: 10.3389/ti.2024.13029.

Fine-tuning tumor- and allo-immunity: advances in the use of immune checkpoint inhibitors in kidney transplant recipients.

Van Meerhaeghe T, Murakami N, Le Moine A, Brouard S, Sprangers B, Degauque N Clin Kidney J. 2024; 17(4):sfae061.

PMID: 38606169 PMC: 11008728. DOI: 10.1093/ckj/sfae061.

Incidence and risk factors for cancer in people with type 1 diabetes, stratified by stages of diabetic kidney disease: a nationwide Finnish cohort study.

Feodoroff M, Harjutsalo V, Makimattila S, Groop P Lancet Reg Health Eur. 2024; 40:100884.

PMID: 38533378 PMC: 10964474. DOI: 10.1016/j.lanepe.2024.100884.

References

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B . Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003; 89(7):1221-7. PMC: 2394311. DOI: 10.1038/sj.bjc.6601219. View

Papadimitriou J, Randhawa P, Rinaldo C, Drachenberg C, Alexiev B, Hirsch H . BK Polyomavirus Infection and Renourinary Tumorigenesis. Am J Transplant. 2016; 16(2):398-406. DOI: 10.1111/ajt.13550. View

Villeneuve P, Schaubel D, Fenton S, Shepherd F, Jiang Y, Mao Y . Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007; 7(4):941-8. DOI: 10.1111/j.1600-6143.2007.01736.x. View

Dharnidharka V, Tejani A, Ho P, Harmon W . Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002; 2(10):993-8. DOI: 10.1034/j.1600-6143.2002.21019.x. View

Acuna S, Huang J, Scott A, Micic S, Daly C, Brezden-Masley C . Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant. 2016; 17(1):103-114. DOI: 10.1111/ajt.13978. View

Batabyal P, Chapman J, Wong G, Craig J, Tong A . Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?. Transplantation. 2012; 94(7):703-13. DOI: 10.1097/TP.0b013e3182637078. View

Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D . Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004; 78(4):584-90. DOI: 10.1097/01.tp.0000129812.68794.cc. View

Brennan D, Flavin K, Lowell J, Howard T, Shenoy S, Burgess S . A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999; 67(7):1011-8. DOI: 10.1097/00007890-199904150-00013. View

Kasiske B, Cangro C, Hariharan S, Hricik D, Kerman R, Roth D . The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2002; 1 Suppl 2:3-95. View

10.

Sampaio M, Cho Y, Qazi Y, Bunnapradist S, Hutchinson I, Shah T . Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. Transplantation. 2012; 94(10):990-8. DOI: 10.1097/TP.0b013e318270bc7b. View

11.

Saeian K, Franco J, Komorowski R, Adams M . Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. Liver Transpl Surg. 1999; 5(1):46-9. DOI: 10.1002/lt.500050106. View

12.

Yanik E, Clarke C, Snyder J, Pfeiffer R, Engels E . Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. J Am Soc Nephrol. 2015; 27(5):1495-504. PMC: 4849829. DOI: 10.1681/ASN.2015040373. View

13.

Pedotti P, Poli F, Longhi E, Frison S, Caldara R, Chiaramonte S . Epidemiologic study on the origin of cancer after kidney transplantation. Transplantation. 2004; 77(3):426-8. DOI: 10.1097/01.TP.0000111757.08499.C2. View

14.

Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D . Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005; 173(10):S1-25. PMC: 1330435. DOI: 10.1503/cmaj.1041588. View

15.

Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M . Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009; 20(6):1385-92. PMC: 2689909. DOI: 10.1681/ASN.2008101037. View

16.

Feng S, Buell J, Cherikh W, Deng M, Hanto D, Kauffman H . Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation. 2002; 74(12):1657-63. DOI: 10.1097/00007890-200212270-00001. View

17.

Chen A, Martin A, Choy B, Fernandez-Penas P, Dalziell R, McKenzie C . A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015; 373(17):1618-26. DOI: 10.1056/NEJMoa1506197. View

18.

Kauffman H, McBride M, Cherikh W, Spain P, Marks W, Roza A . Transplant tumor registry: donor related malignancies. Transplantation. 2002; 74(3):358-62. DOI: 10.1097/00007890-200208150-00011. View

19.

Knoll G, Blydt-Hansen T, Campbell P, Cantarovich M, Cole E, Fairhead T . Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidney Dis. 2010; 56(2):219-46. DOI: 10.1053/j.ajkd.2010.05.004. View

20.

Yan L, Salama M, Lanciault C, Matsumura L, Troxell M . Polyomavirus large T antigen is prevalent in urothelial carcinoma post-kidney transplant. Hum Pathol. 2015; 48:122-31. DOI: 10.1016/j.humpath.2015.09.021. View